Michael Becker to Urate Oxidase
This is a "connection" page, showing publications Michael Becker has written about Urate Oxidase.
Connection Strength
1.646
-
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60.
Score: 0.488
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
Score: 0.446
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
Score: 0.129
-
Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
Score: 0.122
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
Score: 0.118
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
Score: 0.102
-
Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
Score: 0.086
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
Score: 0.083
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
Score: 0.071